Blog Post by Admin
Blog
May 17, 2019
Correlated or causal? Exchangeability and propensity score modeling explained
When designing comparative studies, epidemiologists aim for exchangeability between ...
Start Reading
Blog
May 10, 2019
Methods, approaches, and predictions: Dr. Jessica Franklin discusses RCT DUPLICATE
Known as a “methods wiz” among her collaborators, Jessica Franklin, Ph.D., dedicates her ...
Start Reading
Blog
May 3, 2019
Do real-world evidence studies require a separate registry? A conversation with Richard Willke, Ph.D., Chief Science Officer, ISPOR
As FDA intensifies its focus on real-world evidence (RWE) and the work to establish ...
Start Reading
Blog
Apr 26, 2019
Future sources of real-world data: Opportunities and challenges
Today, real world data (RWD) primarily consists of administrative claims databases, ...
Start Reading
Blog
Apr 20, 2019
A shared learning process: 3 takeaways from the Harvard-MIT Center for Regulatory Science’s annual meeting
Academe, U.S. Food and Drug Administration (FDA) staff, and industry leaders gathered at ...
Start Reading
Blog
Apr 12, 2019
Real-world evidence use cases: A round up of essential sources of information
For those looking to learn more about real-world evidence (RWE), there is a wealth of ...
Start Reading
Blog
Apr 5, 2019
A perfect data set? Yes and no: The All of Us Project
In an ideal world, all health data would be meticulously collected, capture the whole ...
Start Reading
Blog
Mar 21, 2019
Real-world evidence shows that prescription amphetamine use increases risk of psychosis in ADHD
Five million people under the age of 25 in the U.S. are prescribed stimulants to treat ...
Start Reading
Blog
Mar 15, 2019
Why does traceability data matter—and how do platforms help?
When considering the use of real-world evidence (RWE) for decision-making purposes, we ...
Start Reading
Blog
Mar 8, 2019
The epidemiology of databases: Part III: The expanding uses of real-world evidence
Part I: Four principles of working with real-world data
Start Reading
Blog
Mar 2, 2019
The perils of immortal time bias
In the early 2000s, a study published in the Annals of Internal Medicine reported that ...
Start Reading
Blog
Feb 23, 2019
The epidemiology of databases: Part II: Four principles of generating real-world evidence
In a recent comment letter to the U.S. Food and Drug Administration, Aetion outlined key ...
Start Reading
Blog
Feb 16, 2019
The epidemiology of databases: Part I: Four principles of working with real-world data
As the U.S. Food and Drug Administration continues its formal exploration of the use of ...
Start Reading
Blog
Feb 8, 2019
Where public health and quantitative science overlap: A conversation with senior scientist Erin Comerford
Health care tech and data grab all the headlines, but science matters most. Erin ...
Start Reading
Blog
Feb 1, 2019
Welcome to the Evidence Hub
At Aetion, we work at the crossroads of health care: the point at which patients, ...
Start Reading
Blog
Jan 31, 2019
Framework for FDA’s Real-World Evidence Program: Dr. Sebastian Schneeweiss considers implications for biopharma
In December 2018, the U.S. Food and Drug Administration unveiled its strategy to assess ...
Start Reading
Blog
Jan 31, 2019
Leading change at Pfizer: A conversation with Chris Boone
As costs soar and patients wait, forward-looking pharmaceutical companies are exploring ...
Start Reading
Blog
Jan 31, 2019
Four questions to ask your data
A vital step in generating real-world evidence is understanding where the available data ...
Start Reading
Blog
Jan 31, 2019
A year of acceleration: Looking ahead at 2019
The place where two rivers meet is called a confluence—a good word for the year ahead in ...
Start Reading